At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 40 target
Drug / intervention
Afatinibdrug
Likely dose
Afatinib 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of Afatinib in Previously Treated Recurrent or Metastasic Esophageal Squamous Cell Carcinoma With EGFR Overexpression or EGFR Amplification (ESCC-A01)
In Brief
A Phase 2 clinical trial evaluating Afatinib for Esophageal Squamous Cell Carcinoma. Targeting 40 participants across 1 site.
Detailed Summary
This is a phase 2 trial investigating the effect and safety of afatinib in previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR amplification.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Squamous Cell Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
2020202120222023202420252026
Enrollment StartApr 2019
First PostedMay 2019
Primary CompletionJan 2020
Study CompletionMay 2020
TodayJul 2026
First PostedMay 7, 2019
Enrollment StartApr 28, 2019
Primary CompletionJan 1, 2020
Study CompletionMay 1, 2020
TodayJul 1, 2026
Enrollment to primary: 8 monthsPosted 7.1 years ago
Interventions
Afatinibdrug
Afatinib is orally administered at 40mg Qd of each 28 day cycle.